Related Experiment Video

Updated: Aug 9, 2026

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

CD26/dipeptidyl peptidase IV and its role in cancer

B Pro1, N H Dang

  • 1Department of Lymphoma/Myeloma, Unit 429, M.D. Anderson Cancer Center, Houston, TX 77303, USA.

Histology and Histopathology
|September 18, 2004
PubMed

Insights

CD26/Dipeptidyl Peptidase IV (DPPIV) is an enzyme involved in immune regulation and cell signaling. This review highlights its significant role in tumor biology, cancer development, and progression.

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • CD26/Dipeptidyl Peptidase IV (DPPIV) is a cell surface glycoprotein with diverse biological functions.
  • Its enzymatic activity involves proline-containing peptides, impacting growth factors, chemokines, and neuropeptides.
  • DPPIV is implicated in immune regulation, signal transduction, and apoptosis.

Purpose of the Study:

  • To review the key aspects of CD26/DPPIV involvement in tumor biology.
  • To explore the potential role of CD26/DPPIV in cancer development and behavior.

Main Methods:

  • Literature review of studies on CD26/DPPIV and cancer.
  • Synthesis of current knowledge on CD26/DPPIV's functions and interactions.
  • Analysis of CD26/DPPIV's role in tumor progression.

Main Results:

  • CD26/DPPIV exhibits significant enzymatic activity and interacts with various molecules.
  • The enzyme plays a crucial role in immune system regulation and cellular signaling pathways.
  • Evidence suggests CD26/DPPIV is involved in tumor progression and cancer behavior.

Conclusions:

  • CD26/DPPIV is a key player in biological processes relevant to cancer.
  • Understanding CD26/DPPIV's role may offer insights into cancer development and treatment strategies.

More Related Videos

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD22608:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However, invadopodia can...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.